ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
94,700
-100 (-0.11%)
Aug 28, 2025, 3:30 PM KST
-0.11%
Market Cap5.17T
Revenue (ttm)94.93B
Net Income (ttm)-20.52B
Shares Out54.58M
EPS (ttm)-424.97
PE Ration/a
Forward PE158.41
Dividendn/a
Ex-Dividend Daten/a
Volume657,793
Average Volume1,168,195
Open95,200
Previous Close94,800
Day's Range93,000 - 97,400
52-Week Range25,950 - 96,800
Beta0.77
RSI67.79
Earnings DateAug 11, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.